Neonatal jaundice affects up to 60% of term and 80% of preterm infants and is most commonly benign physiologic hyperbilirubinemia, though it can rarely progress to kernicterus (~1 in 100,000 in high-income countries) if severe hyperbilirubinemia is missed. [1-2] The following is a clinically focused summary based on the 2022 AAP Clinical Practice Guideline and supporting evidence.
The following diagnostic algorithm provides a practical framework for evaluating neonatal jaundice based on timing of onset:
1. History
- Onset timing: Jaundice <24 hours = pathologic until proven otherwise (likely hemolytic); days 2–5 = physiologic peak; >2 weeks (term) or >3 weeks (preterm) = prolonged jaundice requiring workup [4]
- Feeding history: Breastfeeding vs. formula; frequency, duration, latch quality; number of wet/dirty diapers; weight loss from birth weight — suboptimal breastfeeding intake is a major risk factor [4]
- Stool color: Pale/acholic stools suggest conjugated hyperbilirubinemia (biliary atresia) [4]
- Birth history: Gestational age, delivery type (vacuum/forceps → cephalohematoma), oxytocin use, birth trauma/bruising [2][5]
- Maternal blood type and Rh status: ABO/Rh incompatibility; whether Rh(D) immune globulin was given during pregnancy [6]
- Prior sibling history: Jaundice requiring phototherapy or exchange transfusion [4]
2. Alarm Features
- Jaundice within the first 24 hours of life — strongly suggests hemolytic disease; requires immediate TSB/TcB [4]
- Signs of acute bilirubin encephalopathy (ABE): Lethargy, poor feeding, high-pitched cry, hypertonia, arching, retrocollis, opisthotonos, recurrent apnea [4][7]
- Rapid TSB rise: >0.3 mg/dL/hr in first 24 hours or >0.2 mg/dL/hr thereafter suggests hemolysis [6]
- TSB approaching escalation-of-care threshold (2 mg/dL below exchange transfusion threshold) [4]
- Pale/acholic stools + dark urine → conjugated hyperbilirubinemia, possible biliary atresia [4]
- Fever, irritability, poor feeding → consider sepsis as both a cause and neurotoxicity risk factor [6]
- Conjugated/direct bilirubin ≥5 mg/dL → urgent GI consultation [1]
3. Medications
- Phototherapy is the primary treatment; intensive phototherapy requires narrow-spectrum LED blue light (≥30 µW/cm² per nm at ~475 nm wavelength) [4]
- IVIG (0.5–1 g/kg over 2 hours, may repeat in 12 hours) for isoimmune hemolytic disease (positive DAT) when TSB reaches escalation-of-care threshold; effectiveness is uncertain and there is an association with necrotizing enterocolitis [4]
- Rh(D) immune globulin — maternal prenatal administration prevents Rh hemolytic disease
- Avoid: Sulfonamides, ceftriaxone, and other drugs that displace bilirubin from albumin in neonates
- Phenobarbital is rarely used but can induce hepatic conjugation in select cases (e.g., Crigler-Najjar type II)
- Caution with G6PD deficiency: Avoid oxidant drugs (e.g., naphthalene, certain antimalarials) that can trigger hemolysis [5][8]
4. Diet
- Continue breastfeeding — discontinuation is not necessary and should be discouraged; mothers of jaundiced infants are more likely to stop breastfeeding unnecessarily [1]
- Optimize breastfeeding frequency: 8–12 feeds per day to promote stooling and bilirubin excretion; lactation support is critical [8]
- Supplementation: If breastfeeding is suboptimal and the infant has significant weight loss (>8–10% of birth weight), supplementation with expressed breast milk or formula may be considered
- IV hydration is indicated during escalation of care but does not replace feeding [4][6]
5. Review of Systems
- Neuro: Lethargy, poor tone, high-pitched cry, seizures (ABE signs)
- GI: Feeding adequacy, stool color/frequency, vomiting (pyloric stenosis with Gilbert syndrome can cause prolonged jaundice) [4]
- Heme: Pallor (anemia from hemolysis), bruising, cephalohematoma
- Infectious: Fever, temperature instability, irritability (sepsis)
- Metabolic: Poor feeding, vomiting, failure to thrive (inborn errors of metabolism)
- Endocrine: Constipation, prolonged jaundice, macroglossia (hypothyroidism)
6. Collateral History and Family History
- Maternal blood type and Rh status — essential for identifying ABO/Rh incompatibility [8]
- Family history of jaundice, phototherapy, or exchange transfusion in siblings [4]
- Genetic ancestry suggestive of G6PD deficiency (African, Mediterranean, Southeast Asian descent), hereditary spherocytosis, or other RBC disorders [5][8]
- Family history of Gilbert syndrome, Crigler-Najjar syndrome [4-5]
- Social context: Access to follow-up care, parental health literacy regarding jaundice detection, barriers to care-seeking [8]
7. Risk Factors
Per the 2022 AAP guideline, risk factors for developing significant hyperbilirubinemia include: [4]
- Lower gestational age (risk increases with each week <40 weeks)
- Jaundice in the first 24 hours
- Predischarge TcB/TSB close to phototherapy threshold
- Hemolysis (rate of rise >0.3 mg/dL/hr in first 24 hours or >0.2 mg/dL/hr thereafter)
- Prior phototherapy before discharge
- Sibling requiring phototherapy or exchange transfusion
- Family history/genetic ancestry suggestive of G6PD deficiency or other RBC disorders
- Exclusive breastfeeding with suboptimal intake
- Scalp hematoma or significant bruising
- Down syndrome
- Macrosomic infant of a diabetic mother
Neurotoxicity risk factors (lower treatment thresholds): GA <38 weeks, albumin <3.0 g/dL, isoimmune hemolytic disease, G6PD deficiency, other hemolytic conditions, sepsis, clinical instability in prior 24 hours [1][6]
8. Differential Diagnosis
- Physiologic jaundice — most common; onset day 2–5, peaks day 3–5, resolves by 1–3 weeks [1]
- Breastfeeding jaundice — early, related to suboptimal intake and dehydration
- Breast milk jaundice — prolonged unconjugated hyperbilirubinemia beyond 2 weeks, benign [4]
- ABO/Rh hemolytic disease — early onset, positive DAT, rapid TSB rise [2][5]
- G6PD deficiency — can present acutely with hemolysis; overrepresented in kernicterus cases [8]
- Hereditary spherocytosis / other RBC membrane defects [5]
- Sepsis/UTI — can elevate both conjugated and unconjugated bilirubin [4]
- Biliary atresia — conjugated hyperbilirubinemia, acholic stools, dark urine; prevalence ~1 in 14,000 [4]
- Hypothyroidism — prolonged jaundice; check newborn screen [4]
- Crigler-Najjar syndrome — rare, severe unconjugated hyperbilirubinemia [4-5]
- Galactosemia, tyrosinemia — inborn errors of metabolism detected on newborn screen [4]
- Cephalohematoma / subgaleal hemorrhage — extravascular blood breakdown [2]
9. Past Medical History
- Gestational age and birth weight
- Birth trauma (vacuum, forceps, bruising)
- Prior episodes of jaundice or phototherapy during birth hospitalization
- Newborn screening results (hypothyroidism, galactosemia, G6PD where screened)
- Maternal conditions: diabetes (macrosomic infant), infections, blood type
- Prenatal Rh(D) immune globulin administration status
10. Physical Exam
- Vital signs: Temperature instability (sepsis), heart rate (anemia/sepsis)
- Skin: Cephalocaudal progression of jaundice (face → trunk → extremities); blanch skin in natural light to assess — but visual estimation is unreliable (differences up to 13–15 mg/dL from actual TSB) [4]
- Scleral icterus: May be the earliest detectable sign, especially in darker-skinned infants [8]
- Head: Cephalohematoma, caput succedaneum, subgaleal hemorrhage
- Abdomen: Hepatosplenomegaly (hemolytic disease, hepatobiliary pathology)
- Neurologic: Tone (hypotonia early → hypertonia late in ABE), reflexes, cry quality, feeding behavior [7]
- Hydration status: Fontanelle, mucous membranes, skin turgor, weight change from birth
- Stool color: Acholic stools warrant urgent evaluation for biliary atresia [4]
11. Lab Studies
- TSB or TcB: Universal screening recommended between 24–48 hours of age or before discharge [6]
- Direct (conjugated) bilirubin: Obtained with TSB; direct ≥1.0 mg/dL is abnormal; ≥5 mg/dL warrants urgent GI consult [1][4]
- Blood type and DAT (Coombs): On infant if mother is type O or Rh-negative [8]
- CBC with reticulocyte count: Evaluate for hemolysis and anemia
- Peripheral smear: Spherocytes (ABO incompatibility, hereditary spherocytosis)
- G6PD level: Especially if phototherapy required, or in at-risk populations [8]
- Serum albumin: <3.0 g/dL is a neurotoxicity risk factor [6]
- For escalation of care: STAT TSB + direct bilirubin, CBC, albumin, serum chemistries, type and crossmatch [4][6]
- Prolonged jaundice workup: TSH, newborn screen review, urine culture, fractionated bilirubin [4]
12. Imaging
- Not routinely indicated for uncomplicated neonatal jaundice
- Abdominal ultrasound: If conjugated hyperbilirubinemia is present — evaluate for biliary atresia (absent/small gallbladder, triangular cord sign), choledochal cyst
- Hepatobiliary iminodiacetic acid (HIDA) scan: If biliary atresia is suspected and ultrasound is inconclusive
- Head ultrasound: Not routine; consider if neurologic signs suggest bilirubin encephalopathy or other intracranial pathology
13. Special Tests
- Hour-specific bilirubin nomograms (AAP 2022): Plot TSB against age in hours to determine phototherapy threshold, escalation-of-care threshold, and exchange transfusion threshold based on gestational age and neurotoxicity risk factors [4]
- Bilirubin-to-albumin ratio (B/A ratio): Used in conjunction with TSB to determine need for exchange transfusion: [4]
- ≥8.0 if ≥38 weeks GA with no risk factors
- ≥7.2 if ≥38 weeks GA with risk factors or 35–37 weeks GA without risk factors
- ≥6.8 if 35–37 weeks GA with risk factors
- Transcutaneous bilirubinometry (TcB): Non-invasive screening tool; less reliable after phototherapy (wait ≥24 hours post-phototherapy to use) [4][7]
- BIND score (Bilirubin-Induced Neurologic Dysfunction): Clinical scoring for acute bilirubin encephalopathy severity
The following AAFP algorithm operationalizes the AAP guideline for clinical decision-making:
14. ECG
- Not routinely indicated in neonatal jaundice
- Consider if there is concern for myocarditis (in the setting of sepsis) or electrolyte abnormalities from dehydration or exchange transfusion
- Post-exchange transfusion: Monitor for hypocalcemia (citrate in blood products) which can cause QT prolongation
15. Assessment
- Most cases are physiologic and benign — unconjugated bilirubin peaks days 2–5, resolves by 1–3 weeks without intervention [1]
- Severity stratification is based on TSB plotted on hour-specific nomograms relative to gestational age and neurotoxicity risk factors [4]
- Atypical presentations warranting concern: onset <24 hours, rapid rise, conjugated hyperbilirubinemia, prolonged jaundice >2 weeks (term) or >3 weeks (preterm), neurologic signs [4]
- Complications: Acute bilirubin encephalopathy → chronic kernicterus (athetoid cerebral palsy, sensorineural hearing loss, gaze palsy, dental dysplasia) [7]
- Key pearl: The 2022 AAP guideline raised phototherapy thresholds modestly compared to 2004, reflecting evidence that neurotoxicity occurs at much higher bilirubin levels than previously thought [1][9]
16. Treatment Plan
Initial stabilization (ED/urgent care)
- Obtain STAT TSB; plot on hour-specific nomogram
- If TSB exceeds phototherapy threshold → initiate intensive phototherapy immediately (narrow-spectrum LED blue light, ≥30 µW/cm²/nm, maximize skin surface area exposure) [4]
- Ensure adequate feeding; supplement if needed
Phototherapy management
- Recheck TSB 4–8 hours after starting phototherapy; expect decline of 1–2 mg/dL in first 4–6 hours [4]
- Continue phototherapy until TSB is ≥2 mg/dL below the phototherapy threshold [4]
- Monitor for rebound: recheck TSB 6–24 hours after stopping phototherapy depending on risk [4]
Escalation of care (TSB within 2 mg/dL of exchange transfusion threshold):
- NICU admission; emergent intensive phototherapy + IV hydration [4][6]
- STAT labs: TSB + direct, CBC, albumin, chemistries, type and crossmatch [4]
- IVIG (0.5–1 g/kg) for isoimmune hemolytic disease (positive DAT) [4]
- TSB every 2 hours until below escalation threshold [4]
Exchange transfusion
- Indicated when TSB reaches exchange transfusion threshold or signs of intermediate/advanced ABE regardless of TSB level [4]
- Double-volume exchange with cross-matched washed packed RBCs mixed with FFP to Hct ~40% [4]
17. Disposition
- Discharge criteria: TSB trending down and ≥2 mg/dL below phototherapy threshold; adequate feeding; reliable follow-up arranged [1][4]
- Admission criteria: TSB at or above phototherapy threshold (if outpatient phototherapy unavailable); TSB within 2 mg/dL of exchange transfusion threshold (→ NICU); signs of ABE [4][6]
- Observation: TSB close to but below phototherapy threshold with risk factors; recheck in 4–24 hours depending on proximity to threshold [1]
- Specialist consultation triggers:
- Neonatology: Escalation of care, exchange transfusion consideration [4]
- Pediatric GI: Conjugated bilirubin ≥5 mg/dL, suspected biliary atresia, prolonged conjugated hyperbilirubinemia [1][4]
- Hematology: Suspected hemolytic disease, G6PD deficiency, hereditary spherocytosis
18. Follow-Up / Return Precautions
Follow-up timing (based on difference between TSB and phototherapy threshold at discharge): [1][4]
- TSB within 1.9 mg/dL of threshold → recheck TSB in 4–24 hours
- TSB 2.0–3.4 mg/dL below threshold → TcB/TSB in 4–24 hours
- TSB 3.5–5.4 mg/dL below threshold → TcB/TSB in 1–2 days
- TSB 5.5–6.9 mg/dL below threshold (discharged <72 hours) → follow-up within 2 days
- TSB ≥7.0 mg/dL below threshold (discharged <72 hours) → follow-up within 3 days
Post-phototherapy follow-up: Recheck bilirubin 6–12 hours after stopping if high-risk (phototherapy <48 hours of age, positive DAT, hemolytic disease); otherwise next day [4]
Return precautions — counsel parents on: [4]
- Increasing yellow discoloration of skin/eyes
- Poor feeding, decreased wet/dirty diapers
- Excessive sleepiness, difficulty waking for feeds
- High-pitched cry, arching of back, stiffness
- Fever or temperature instability
- Pale/white stools (biliary atresia)
Expected course: Physiologic jaundice peaks days 3–5 and resolves by 1–2 weeks in formula-fed and 2–3 weeks in breastfed infants. [1] Breast milk jaundice may persist up to 12 weeks but is benign if unconjugated and the infant is thriving.
References
1. Neonatal Hyperbilirubinemia: Evaluation and Treatment. — Par EJ, Hughes CA, DeRico P. American Family Physician. 2023.
2. High- Versus Low-Dose Phototherapy for Neonatal Jaundice. — Lai NM, Ahmad Kamar A, Lee SWH, et al. The Cochrane Database of Systematic Reviews. 2026.
3. Neonatal Jaundice. — Rebecca Puddifoot Clinical Guide to Paediatrics. 2022.
4. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. — Kemper AR, Newman TB, Slaughter JL, et al. Pediatrics. 2022.
5. Neonatal Hyperbilirubinaemia: A Global Perspective. — Olusanya BO, Kaplan M, Hansen TWR. The Lancet. Child & Adolescent Health. 2018.
6. Hyperbilirubinemia in Newborns: Updated Guidelines From the AAP. — Espinosa K, Brown SR. American Family Physician. 2023.
7. Transcutaneous Bilirubinometry Versus Total Serum Bilirubin Measurement for Newborns. — Okwundu CI, Olowoyeye A, Uthman OA, et al. The Cochrane Database of Systematic Reviews. 2023.
8. Combating the Hidden Health Disparity of Kernicterus in Black Infants: A Review. — Okolie F, South-Paul JE, Watchko JF. JAMA Pediatrics. 2020.
9. Bilirubin Measurement and Phototherapy Use After the AAP 2022 Newborn Hyperbilirubinemia Guideline. — Sarathy L, Chou JH, Romano-Clarke G, Darci KA, Lerou PH. Pediatrics. 2024.